Q&A

How antidepressant myths can raise suicide risk—and what evidence-based prescribing, tapering, and crisis supports really look like.

HHS targets psychiatric overprescribing; expert Joseph F. Goldberg, MD, urges careful deprescribing—stop ineffective medications and replace with evidence-based treatments.

Explore how neuromelanin-sensitive MRI noninvasively tracks long-term dopamine and noradrenaline system changes.

Low soluble α2δ‑1 disrupts brain excitation‑inhibition balance in schizophrenia.

New data shows stable symptoms when switching from atypical antipsychotics to Cobenfy using cross-titration.

Read our exclusive interview with Daniel R. Karlin, MD, MA, on the latest executive order, DT120 for the treatment of mental health disorders, and more.

Study links schizophrenia’s earlier onset to higher genomic deletion CNV burden, showing future potential for personalized care.

How do estrogen, testosterone, and aromatase shape binge eating and bulimia risk? Let's explore brain biomarkers and future hormone-aware treatments.

Psychiatry experts explain why off-label psych meds and polypharmacy can be essential.

ASAM’s new youth SUD criteria help clinicians deliver developmentally tailored, prevention-first care with coordinated family and community supports.

Faster aging may be linked to schizophrenia, according to new research.

A pharma expert and clinician shares perspectives on developing treatments.

New ASAM youth criteria redefine SUD care with brain-stage levels, chronic monitoring, detox safety, and family-centered support.

Experts share how roluperidone provides a new opportunity in the schizophrenia treatment landscape.

New analysis links traumatic brain injury to later psychosis, prompting long-term screening and follow-up.

Remote QbCheck testing tracks ADHD treatment progress.

Early psychosis screening in teens and young adults helps catch overlooked symptoms sooner.

Active Minds is pushing for 988 Lifeline information to be shared on student IDs, boosting crisis access and youth-led policy action to curb suicide and reshape campus support.

Brief interpersonal therapy in pregnancy sharply lowers depression and postpartum relapse for a year—offering clinicians a fast, safe option.

New research highlights psilocybin's potential in treating treatment-resistant OCD, while cannabinoids show little evidence of efficacy.

Research reveals links between gut microbiome composition and cognitive decline in Alzheimer disease and mild cognitive impairment.

Discover insights from Lauren Kenworthy, PhD on treating comorbid ADHD and autism.

Researchers discuss precision medicine's potential to enhance opioid use disorder treatment.

Explore the complex relationship between gender, sexual health, and mental health with insights from expert Eugene T. Lucas Jr, DNP, CRNP, FNP-BC, APMHNP-BC.

Clinicians can guide patients with bipolar disorder in setting flexible, achievable New Year’s goals, enhancing motivation and stability throughout mood fluctuations.